Related Experiment Video
Updated: Jul 31, 2026
Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
Recent data with anti-epidermal growth factor receptor antibodies and irinotecan in colon cancer
1Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK.
Abstract:
The epidermal growth factor receptor (EGFR) is overexpressed in the majority of colorectal cancers. It is the target for a class of agents at the forefront of development for the treatment of colorectal cancer, ie, the anti-EGFR monoclonal antibodies, which include cetuximab, panitumumab, and matuzumab. At present, cetuximab is the furthest along in terms of established efficacy in the treatment of metastatic or inoperable disease and is licensed for the treatment of patients with irinotecan-refractory colorectal cancer. This article reviews the recent evidence supporting the combination of these anti-EGFR agents with the cytotoxic chemotherapeutic agent irinotecan.
Insights
The epidermal growth factor receptor (EGFR) is a key target in colorectal cancer treatment. Combining anti-EGFR monoclonal antibodies with irinotecan chemotherapy shows promising efficacy for advanced disease.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Epidermal growth factor receptor (EGFR) is overexpressed in most colorectal cancers.
- Anti-EGFR monoclonal antibodies are a promising therapeutic class for colorectal cancer.
- Cetuximab demonstrates established efficacy in metastatic or inoperable colorectal cancer.
Purpose of the Study:
- To review recent evidence on combining anti-EGFR agents with irinotecan.
- To evaluate the efficacy of combination therapy in colorectal cancer treatment.
Main Methods:
- Literature review of recent clinical evidence.
- Analysis of studies combining anti-EGFR monoclonal antibodies (cetuximab, panitumumab, matuzumab) with irinotecan.
Main Results:
- Evidence supports the combination of anti-EGFR agents with irinotecan.
- Cetuximab is licensed for irinotecan-refractory colorectal cancer.
- Combination therapy shows potential in advanced colorectal cancer.
Conclusions:
- Combining anti-EGFR monoclonal antibodies with irinotecan is a viable strategy for colorectal cancer.
- Further research into combination therapies is warranted.
- These combinations represent a forefront in colorectal cancer treatment development.
